| abstract |
Second medical application of epirubicine hydrochloride as an active substance inhibiting the hepatitis C virus (HCV) replication while having low toxicity in Huh7 cells. nEpirubicine hydrochloride is employed in therapy of HCV infections. nPharmaceutically accepted forms of the anti-HCV drug, best if applied as water solutions suited for injections, according to the invention, are distinguished by containing epirubicine hydrochloride applied at cumulated, antiviral therapeutic doses comprising 1 - 100 mg/m 2 of body surface (0,02 - 2 mg; 0,0344 - 3,44 µM per kg of body weight). |